Recent Lung Cancer News

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients (January 15, 2018)

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (January 8, 2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway,... Continue Reading

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer (January 8, 2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages... Continue Reading

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer (December 6, 2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy –... Continue Reading

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer (October 17, 2017)

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are... Continue Reading

FDA Approves Aliqopa for Relapsed Follicular Lymphoma (October 4, 2017)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment... Continue Reading

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients (July 6, 2017)

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line... Continue Reading

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation (June 26, 2017)

The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer... Continue Reading

Alecensa Superior to Xalkori in Treatment of Lung Cancer (June 12, 2017)

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the... Continue Reading

Next Page »